CARDIOLOGS
1.9.2020 08:02:13 CEST | Business Wire | Press release
Cardiologs , a global leader in artificial intelligence (AI) cardiology diagnostics, today announced an exclusive distribution agreement in France with MicroPort CRM , for the reselling of its cloud analysis solution for Holter ECGs. MicroPort CRM is a worldwide leader in the conception and distribution of implementable devices for the treatment of heart rhythm disorders and the leader in France of Holter ECG monitoring devices and software. This agreement marks the official launch, at a large scale, of Cardiologs’ European business operations.
As a pioneer in AI-based healthcare, Cardiologs is the first company to obtain a CE mark for an AI-based medical device. Cardiologs’ medical-grade AI automatically identifies cardiac rhythm disorders with a high level of accuracy and in a timely manner, cutting diagnosis and analysis time in half. Thanks to its secure cloud solution, which General Data Protection Regulations (GDPR) compliant and “Hébergeur de Données de Santé” (HDS) certified, the analysis is available in real-time, from everywhere, by all professionals involved in a patient’s care, thus simplifying the logistics of ECG diagnostics.
Cardiologs is device-agnostic and can interpret data from a broad range of cardiac monitoring devices, a choice aligned with the evolution of health tech towards greater openness and interoperability. Already in use in several healthcare facilities, Cardiologs’ solution has been immediately endorsed by the medical staff, as Dr. Laurent Fiorina, rythmolog at Institut Cardiovasculaire de Paris-Sud (France) and medical expert at Cardiologs confirms, “Cardiologs’ solution enabled us to be more efficient and doubled our Holter analysis capacity. We are now capable of providing our patients with fast and accurate ECG analysis. The ease of use was a major reason for the team’s fast endorsement of this new ECG analysis device.”
Yann Fleureau, co-founder and CEO of Cardiologs, said, “We are extremely enthusiastic to partner with MicroPort CRM for the distribution of our unique technology in France. Its leading position in the Holter market combined with the expertise of its business teams, makes MicroPort CRM an ideal business partner to widely distribute Cardiologs’ solution to all the French cardiologists in hospitals as well as in outpatient medical offices.”
Benoît Clinchamps, President of MicroPort CRM, adds: “We are very happy to launch this partnership with Cardiologs which perfectly reflects MicroPort CRM’s strategy: to offer new unique and innovative services that enable healthcare facilities and cardiologists to optimize their time, resources and improve patient diagnostics.”
France Schwarz, Director of Marketing Europe at Cardiologs added, “This agreement confirms our solution’s attractiveness and marks the first phase of our European marketing strategy.”
About Cardiologs
Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology. Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently. CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 5 million ECG recordings and is supported by a number of clinical publications.
For more information: https://cardiologs.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005648/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 07:00:00 CEST | Press release
FDA Fast Track Designation granted to 4P004 for the treatment of knee osteoarthritis, recognizing the disease as a serious condition with significant unmet medical need Designation supports enhanced regulatory interactions and alignment on efficient post-Phase 2a development strategies, including potential accelerated pathways 4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlight
LTM Wins Two Google Cloud Partner of the Year Awards for 202622.4.2026 04:30:00 CEST | Press release
Recognised for its Media & Entertainment Industry Solutions and Infrastructure Modernization at Scale LTM, the Business Creativity partner to the world’s largest enterprises, announced today that it has received two Google Cloud Partner of the Year 2026 Awards. LTM is being recognized for its achievements in the Google Cloud ecosystem, helping joint customers to drive high-impact, scalable cloud transformations. LTM won the Google Cloud Partner of the Year Award in the Media & Entertainment category by modernizing a global media company's complex data estate with BigQuery. The transformation improved speed, lowered costs, and provided a scalable foundation, enabling real-time analytics and AI-ready pipelines. This approach offers a repeatable model for data modernization in Media and Entertainment industry. Additionally, LTM was honoured with another Google Cloud Partner of the Year Award for Infrastructure Modernization in North America and the transformation of the ERP landscape for
Horse Powertrain Reveals Lightweight Hybrid V6 System at Beijing Auto Show 202622.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, has revealed the HORSE W30 – the company’s first production-ready V6 engine – ahead of the Beijing Auto Show 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421176701/en/ The front view of the HORSE W30 engine. The HORSE W30 marks a first for Horse Powertrain, in transferring its expertise in developing optimized three- and four-cylinder engines into the V6 category. By deploying its expertise in this way, Horse Powertrain has developed the lightest V6 on the market and created a hybrid-first V6 with outstanding fuel economy and efficiency. The HORSE W30 is a 3-liter engine that can be fitted in a transverse or longitudinal configuration, allowing it to be packaged in a wide variety of vehicles. The two rows of cylinders are offset at an angle of 90° to lower the engine’s center of gravity, improving ease of installation and optimizi
Montrose Environmental Group Is Now Onterris21.4.2026 22:05:00 CEST | Press release
Earth Day launch of new, unified brand highlights commitment “For Planet & Progress” Montrose Environmental Group (NYSE: MEG, changing to ONT May 4, 2026) will mark Earth Day by rebranding to Onterris. The new, unified brand reflects a purpose and broader role in tackling complex environmental challenges with scientific rigor, operational quality and precise execution. It also aligns expertise and market awareness to position the Company for its next phase of growth. Founded 14 years ago and operating across the U.S., Canada and Australia, the Company is a leading pure-play environmental solutions provider. While the name is new, the mission remains unchanged: advancing our way of life without compromising the integrity of our environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420842892/en/ At the heart of the new brand is a guiding principle: For Planet & Progress. “Onterris is more than a new name. This brand r
SBC Medical Announces Closing of Previously Announced Secondary Public Offering of 3.1 million shares of Common Stock21.4.2026 22:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the closing of its previously announced underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. The proceeds from the offering to the Selling Stockholder were approximately $10.1 million, before deducting underwriting discounts and commissions. The Company did not sell any shares of its common stock in the offering. The Selling Stockholder received all of the proceeds from the offering. Maxim Group LLC acted as the sole book-running manager and Roth Capital Partners acted as the co-manager for the offering. The offering was made pursuant to the Company’s effective shelf registration statement on Form S-3, including a base prospectus, filed with the U.S. Secur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom